Contributing Editor Dr. Adam Mead has a conversation with Dr. Elvin Wagenblast about a study that used CRISPR/Cas9 genome editing of hematopoietic stem and progenitor cells from human fetal liver to induce transient abnormal myelopoiesis– and myeloid leukemia associated with Down syndrome–related mutations.

Genome Editing: Fetal Origins of AML in Down Syndrome, With Drs. Adam Mead & Elvin Wagenblast

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

Science

In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Leslie Ellis, MD, a professor of internal medicine at Atrium Health Wake Forest Baptist in Winston Salem, North Carolina. They discuss the ASH Ambassador Program, which is designed to support the recruitment and retention of trainees into hematology. Dr. Ellis is chair of an ASH oversight subcommittee for that program.

Growing the Next Generation of Hematologists

In this episode, Tamara Dunn, MD, a clinical associate professor of medicine in the division of hematology at Stanford University in Stanford, California, and co-chair of ASH’s Women in Hematology Working Group, hosts a conversation with Toyosi Onwuemene, MD, an associate professor of medicine, specializing in hemostasis/thrombosis, at Duke University in Durham, North Carolina, and Nina Shah, MD, the global clinical head for multiple myeloma research and development at AstraZeneca. They talk about career choices and opportunities for women in hematology, both in academic medicine and industry. Support for this episode provided by Sanofi.

Women in Hematology

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,” published in The New England Journal of Medicine. Dr. Chari wrote about Dr. Sonneveld’s paper in The Hematologist with his Diffusion article, “Four Is Better Than Three: Will We Finally Agree?”  Disclosures: Dr. Chari has received consulting fees from Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme and received research funding from Janssen. Dr. Sonneveld has served on the advisory board of Pfizer and has received research funding and served on the advisory boards of Amgen, Bristol Myers Squibb, Celgene, Janssen, and Karyopharm. Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

Four Is Better Than Three: Will We Finally Agree?

In this episode, Contributing Editor Lori Muffly, MD, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapies at Stanford University in California, talks with Roberta Demichelis, MD, an assistant professor in the department of hematology and oncology at the Salvador Zubirán National Institute of Health Sciences and Nutrición in Mexico City. They discuss access to care for patients with acute lymphoblastic leukemia in low- and middle-income countries, especially among Hispanic populations.  Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

Toward Equity in Access for ALL

In this episode, Contributing Editor Sarah Tasian, MD, associate professor at the University of Pennsylvania School of Medicine and chief of the hematologic malignancies program at the Children’s Hospital of Philadelphia, talks with Rob Pieters, MD, the chief medical officer at the Princess Maxima Center for Pediatric Oncology and professor of pediatric oncology at the University of Utrecht, both in Utrecht, Netherlands. Dr. Pieters is one of the authors of a paper published recently in The New England Journal of Medicine: “Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.” Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

Genome Editing: Fetal Origins of AML in Down Syndrome, With Drs. Adam Mead & Elvin Wagenblast

Download our free app to listen on your phone